Buy SPRO by Jul 9, 2026.

**TLDR** * Their drug is an antibiotic, the first oral carbapenem for complicated UTI's and pyelonephritis. * Phase 3 trial fixed all things the first trial missed, the trial's design is backed by a written SPA agreement with the FDA, and it was stopped early for showing overwhelming efficacy. * They are partnered with GSK, who do all the work from now on while SPRO collects milestone payments and royalties * Has a solid niche and use case that other …